Company intelligence / Profile preview

01 SEIN 03

Ownership: Private
Development stage: Other

Overview

Sein03 is an early-stage biotechnology company focused on the development of novel small molecule therapeutics for the treatment of oncology indications. The company's lead program, often referred to by the internal code 01 SEIN 03, is currently in the pre-clinical stage of development targeting various solid tumors. Sein03 aims to leverage its proprietary drug discovery approach to identify and optimize compounds that can address unmet needs in the cancer treatment landscape. As a private entity, the company maintains a focused pipeline centered on high-impact therapeutic targets within the oncology space.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on 01 SEIN 03.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 01 SEIN 03.

Explore the full profile